Get 15% off pharmacy supplies

Download Vezeeta App now , add promocode PH15 and get the widest coverage, real time order tracking and a hassle-free experience- all in one app

Download Now

Escitapram 10 mg - 10 F.C. Tablets

Box

This page may not cover all the information mentioned in the attached pamphlet of the manufacturing company

Medical Description

Antidepressant, selective serotonin reuptake inhibitor used in the treatment of major depressive disorder, obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder and generalized anxiety disorder.

Indication & Usage

-Major depressive disorder (unipolar): Oral: Initial: 10 mg once daily; dose may be increased in 10 mg increments after ≥1 week based on response and tolerability up to a maximum dose of 20 mg once daily; however, doses up to 30 mg/day are used in practice and may provide further benefit. -Obsessive-compulsive disorder (OCD): Oral: Initial: 10 mg once daily; dose may be increased in 10 mg increments at intervals ≥1 week up to 40 mg once daily. -Panic disorder: Oral: Initial: 5 mg once daily for 3 to 7 days, then increase dose to 10 mg once daily. May further increase at intervals ≥1 week to 20 mg once daily based on response and tolerability. -Posttraumatic stress disorder: Oral: Initial: 10 mg once daily; may gradually increase dose based on response and tolerability up to 40 mg once daily. -Binge eating disorder: Based on limited data: Oral: Initial: 10 mg once daily; may increase based on response and tolerability in 10 mg increments at intervals ≥1 week up to 30 mg/day. -Pediatric dosing: Depression: Oral: Children and Adolescents ≥12 years: Initial: 10 mg once daily; may be increased to 20 mg/day after at least 3 weeks. Autism and Pervasive Developmental Disorders (PDD): Limited data available: Oral: Children and Adolescents 6 to 17 years: Initial: 2.5 mg once daily; may increase if needed to 5 mg/day after 1 week; may then increase at weekly intervals by 5 mg/day if needed and as tolerated; maximum dose: 20 mg/day.

Active Ingredients

Escitalopram

Recommended Doctors

No Recommended Doctors Found

Dosage & Administration

May be administered with or without food.

Side Effects

-Mania, Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants, hyponatremia, acute angle-closure glaucoma, dose-dependent prolonged QT interval, sexual dysfunction in both men and women. -Diarrhea, nausea, ejaculatory disorder, drowsiness, headache, insomnia, diaphoresis, decreased libido, menstrual disease, abdominal pain , constipation, decreased appetite, dyspepsia , flatulence, toothache, vomiting, xerostomia, impotence, urinary tract infection, abnormal dreams, anorgasmia, dizziness, fatigue, lethargy, paresthesia, yawning, back pain , neck pain, shoulder pain, flu-like symptoms, nasal congestion, rhinitis and sinusitis.

Safety Advice

-In case of renal impairment: if the creatinine clearance is <20 ml/minute: Initial: 5 mg once daily; gradually titrate based on tolerability and response with close monitoring for adverse effects (eg, QT prolongation). -In case of hepatic impairment: 10 mg once daily. Some experts recommend initial doses of 5 mg/day for 2 weeks in patients with mild and moderate impairment -Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). -Used with caution in patients with a recent history of myocardial infarction or unstable heart disease. -Hepatic impairment: Use with caution in patients with hepatic impairment. -Renal impairment: Use with caution in patients with severe renal impairment; dosage adjustment may be required. -Seizure disorders: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism. -Elderly: Bioavailability and half-life are increased by 50% in the elderly patient; dosage adjustment may be required. -Incase of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Storage

Store at room temperature.

Drug Interactions

-Agents with antiplatelet properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties. -Agents with blood glucose lowering effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of agents with blood glucose lowering fffects. -Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. -Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents -Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents -Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone. -Esomeprazole: May increase the serum concentration of Escitalopram. -Fluconazole: Escitalopram may enhance the QTc-prolonging effect of Fluconazole. -Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. -Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). -Omeprazole: May increase the serum concentration of Escitalopram. -Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Antidepressants.

Pregnancy & Lactation

-Escitalopram and desmethylcitalopram cross the placenta and are distributed into the amniotic fluid, Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. If treatment for major depressive disorder is initiated for the first time during pregnancy, escitalopram can be considered. -Escitalopram and its desmethylcitalopram (DCT) metabolite are present in breast milk. The relative infant dose (RID) of escitalopram has been calculated to be 3% to 6%, RIDs up to 10.5% have also been located. In general, breastfeeding is considered acceptable when the RID is <10%, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. When first initiating an antidepressant in a breastfeeding patient, agents other than escitalopram are preferred.

Disclaimer

Delivery Address

Add Address

Cancel

Delete